Dr. Grivas on Promising Combination Therapies in Bladder Cancer

Petros Grivas, MD, PhD
Published: Friday, Jan 18, 2019



Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the agents with the greatest potential to extend the durability of immunotherapy in bladder cancer.

It is difficult to predict which combinations will reflect the highest response rates, explains Grivas. With that said, combinations of PD-L1 inhibitors and vaccines have garnered a lot of excitement in the field. At the University of Washington, an ongoing trial is looking at the frontline combination of a checkpoint inhibitor with a vaccine called CV301 in cisplatin-unfit patients.

Additionally, FGFR inhibitors are another class of agents that are likely to progress quickly through the pipeline. In March 2018, the novel pan-FGFR inhibitor erdafitinib was granted a breakthrough therapy designation for the treatment of patients with metastatic urothelial carcinoma. Subsequently, a new drug application with erdafitinib was submitted to the FDA in September 2018 for the treatment of patients with locally advanced or metastatic urothelial carcinoma and FGFR genetic alterations whose tumors progressed following chemotherapy.
SELECTED
LANGUAGE


Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the agents with the greatest potential to extend the durability of immunotherapy in bladder cancer.

It is difficult to predict which combinations will reflect the highest response rates, explains Grivas. With that said, combinations of PD-L1 inhibitors and vaccines have garnered a lot of excitement in the field. At the University of Washington, an ongoing trial is looking at the frontline combination of a checkpoint inhibitor with a vaccine called CV301 in cisplatin-unfit patients.

Additionally, FGFR inhibitors are another class of agents that are likely to progress quickly through the pipeline. In March 2018, the novel pan-FGFR inhibitor erdafitinib was granted a breakthrough therapy designation for the treatment of patients with metastatic urothelial carcinoma. Subsequently, a new drug application with erdafitinib was submitted to the FDA in September 2018 for the treatment of patients with locally advanced or metastatic urothelial carcinoma and FGFR genetic alterations whose tumors progressed following chemotherapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x